Drugs News and Research

RSS

Experts outline best way to predict common heart rhythm disorders

Use the right tool for the job. Today experts outline the best way to identify people most likely to develop common and devastating heart rhythm disorders.

15 Jun 2020

Combination of nelfinar and amodiaquine shows promise for treating COVID-19

Six months into the COVID-19 pandemic, more than 7.4 million people have been infected, and more than 410 000 have died. As yet, there is no treatment or vaccine for the disease.

15 Jun 2020

Dante Labs, Cambridge Cancer Genomics and Nonacus collaborate to provide precision oncology at scale

Dante Labs, Cambridge Cancer Genomics, and Nonacus, today announced that they have signed a collaboration agreement.

15 Jun 2020

Sygnature Discovery supports New York Medical College pharmacologist in the fight against Covid-19

Sygnature Discovery, a leading independent integrated drug discovery and pre-clinical services company, is supporting Professor Sachin Gupte, a pharmacologist at the New York Medical College, in his endeavours to find a drug treatment for the lung damage that can result from Covid-19 infection.

From Sygnature Discovery Limited 15 Jun 2020

New treatment may improve the quality of life for patients with mesothelioma

A novel treatment for advanced mesothelioma is safe and effective and may improve the quality of life for patients who have few treatment options, according to a research abstract presented during a virtual session of the Society of Interventional Radiology's 2020 Annual Scientific Meeting on June 14.

15 Jun 2020

Study aims to identify key genes involved in the body's response to COVID-19 infection

Data from popular home genetic-testing kits could help scientists shed light on why some people who catch coronavirus have no symptoms while others become very ill.

15 Jun 2020

New MRI techniques can improve outcomes in patients with Parkinson's disease

Recently developed MRI techniques used to more precisely target a small area in the brain linked to Parkinson's disease and essential tremor may lead to better outcomes without surgery and with less risk of negative effects, a new study led by UT Southwestern researchers suggests.

15 Jun 2020

Glycans "lock and load" the SARS-CoV-2 spike protein for infection

A new study by scientists from the University of California San Diego, USA and Maynooth University, Ireland and published on the preprint server bioRxiv* in June 2020 reports preliminary results showing that the spike protein of the SARS-CoV-2, as well as its glycan coat, has “hitherto unseen functional and structural” properties. These may be useful in designing novel therapeutics to target this molecule.

14 Jun 2020

Hydroxychloroquine ineffective in animal SARS-CoV-2 infection

A new study by scientists from the U.S and U.K. and published on the preprint server bioRxiv in June 2020 reports that there is no evidence of efficacy for the drug hydroxychloroquine (HCQ) against infection with SARS-CoV-2 in hamsters or macaque models. This finding does not support the current widespread prophylactic and therapeutic use of HCQ in COVID-19.

14 Jun 2020

Steroidal drugs subvert SARS-CoV-2 interaction with ACE2 receptors

A new study by Italian researchers and published online on the preprint server bioRxiv* in June 2020 reports the ability of several existing steroidal drugs to reduce the binding of the SARS-CoV-2 to the ACE2 receptor. This could help define newer strategies using viral entry blockers to reduce viral load.

14 Jun 2020

Remdesivir prevents replication of SARS-CoV-2 in human intestinal organoids

A new German study published on the preprint server bioRxiv* in June 2020 shows that the drug remdesivir can reduce the replication of SARS-CoV-2 in human intestinal organoids.

14 Jun 2020

Effect of human genes on severity and infectivity of SARS-CoV-2

Now, a new paper published on the preprint server medRxiv* reports the results of an analysis of the association between the genetic variants in the patients and the clinical progression of the disease. The study included 332 patients hospitalized with COVID-19 in a single-center, with widely varying laboratory and clinical features. There were 25, 12, and 17 patients with asymptomatic, mild, and critical disease.

14 Jun 2020

Study shows how combining two drugs may be an effective treatment for HLH

Scientists at St. Jude Children's Research Hospital, UCSF Benioff Children's Hospitals and Baylor College of Medicine are investigating how to best treat hemophagocytic lymphohistiocytosis (HLH), a rare immune disorder.

12 Jun 2020

Inhibitory interneurons cause excitation in the developing brain

Brain function depends on inhibitory cells that balance or 'brake' excitation. These neurons allow the brain to process information and also prevent runaway seizures.

12 Jun 2020

Case series: COVID-19 in teriflunomide-treated patients with MS

During the COVID-19 pandemic, patients with multiple sclerosis (MS) and their clinicians have had questions and concerns about whether immunotherapies for MS could influence risk for infection or lead to an unfavorable outcome.

12 Jun 2020

Prodigiosin-based nanoformulation selectively disrupts cancer cells

Together with colleagues from the University of Palermo, KFU employees offer a nano preparation based on biocompatible halloysite nanotubes and bacterial pigment prodigiosin; the latter is known to selectively disrupt cancer cells without damaging the healthy ones.

12 Jun 2020

Human cardiac organoids for modeling physiological conditions during a heart attack

In the U.S., someone has a heart attack every 40 seconds, and yet researchers have not had a model that fully mimics what occurs in the human heart after a heart attack.

12 Jun 2020

Researchers evaluate the impact of drug decriminalization policy in different settings

The prevalence of drug use has increased for decades all around the world despite the strict measures taken. As the traditional prohibitionist drug policy has created social injustice, public health problems, and high social costs, decriminalization of drug use has emerged as a response.

12 Jun 2020

Beta adrenergic agonists can help decrease risk of graft vs. host disease in alloBMT recipients

New preclinical work by a team of researchers from Roswell Park Comprehensive Cancer Center's Transplant and Cellular Therapy Program suggests that the risk of developing acute graft vs. host disease during allogeneic blood/marrow transplant - a potentially curative treatment for selected patients with hematologic disorders - can be decreased using an existing class of drugs called beta adrenergic agonists.

12 Jun 2020

Corrona Psoriasis Registry to present studies at AAD Virtual Meeting Experience

The Corrona® Psoriasis Registry, a joint collaboration between the National Psoriasis Foundation, NPF, and Corrona, LLC, the leading sponsor of registries in immune-mediated diseases, announces that studies from the registry will be presented at the American Academy of Dermatology Virtual Meeting Experience taking place June 12-14, 2020.

12 Jun 2020